Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
0.44% $2.29
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 24.22 mill |
EPS: | 4.85 |
P/E: | 0.470 |
Earnings Date: | Apr 05, 2024 |
SharesOutstanding: | 10.58 mill |
Avg Daily Volume: | 0.0190 mill |
RATING 2024-03-28 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0.470 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.01x |
Company: PE 0.470 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.15 - 2.43 ( +/- 6.07%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-05 | Walker Marlan D | Buy | 70 000 | Common Stock |
2023-12-06 | Walker Marlan D | Sell | 14 500 | Common Stock |
2023-12-07 | Walker Marlan D | Sell | 4 550 | Common Stock |
2023-12-05 | Walker Marlan D | Sell | 70 000 | Restricted Stock Units |
2023-11-15 | Rubric Capital Management Lp | Buy | 877 192 | Common Stock, par value $0.001 per share ("Common Stock") |
INSIDER POWER |
---|
76.91 |
Last 94 transactions |
Buy: 1 627 514 | Sell: 264 866 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.29 (0.44% ) |
Volume | 0.0097 mill |
Avg. Vol. | 0.0190 mill |
% of Avg. Vol | 51.10 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.